3. september · proinvestor.com
Spændende artikel i Financial Times - Curasight
In 2023 and 2024, US drugmaker Lilly, UK pharmaceutical company AstraZeneca, and French company Sanofi all bought start-ups developing radioligand therapies.
Les artikkel